CERBA/VIROCLINICS-DDL
16.12.2021 13:15:08 CET | Business Wire | Press release
Cerba HealthCare, a leading global player in medical diagnosis, today announced it has reached agreement to acquire Viroclinics-DDL, a fast-growing global virology and immunology contract research organization (CRO) from Summit Partners.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216005574/en/
Viroclinics-DDL, employing a total of over 390 scientists and experts, offers a broad range of virology related services in the field of non-clinical and clinical trials, clinical diagnostics, assay development and clinical trial logistics enabling the development of antiviral drugs, vaccines, and other therapies. The acquisition fits perfectly into Cerba HealthCare's strategy aimed at further strengthening its position in the entire diagnostic and clinical trial laboratory services value chain, while providing the most relevant services to patients, the medical community and healthcare industry players. Within the Cerba Research division, Viroclinics-DDL will be able to further broaden its services and access new markets in North America, Asia, and Africa.
Based in the Netherlands, Viroclinics-DDL brings the best scientific expertise in virology, with core competencies across the entire drug development process, from the preclinical phase to market approval, with unique virology assay capabilities and unparalleled experience working with highly pathogenic viruses. With its global network of 38 processing labs, Viroclinics-DDL is able to support large multinational clinical trials. Its strong logistics infrastructure is critical for the swift and safe transport of fragile virology and PBMC (Peripheral Blood Mononuclear Cell) samples from the patient to the lab.
Alongside its historical activities in routine and specialty clinical pathology with sound positions in Europe and Africa, Cerba HealthCare also has a worldwide presence through its expertise in clinical pathology for clinical trials, showcasing the Group’s geographic and expertise diversification to sustain its integrated vision for diagnosis.
Within Cerba HealthCare’s comprehensive Group offering, and ranking under the Cerba Research brand, clinical laboratory and diagnostic solutions for clinical trials have grown considerably over the past years, demonstrating a strong track record in patient recruitment and clinical trial sample testing, as well as in logistics solutions for immuno-oncology, anti-infectives and metabolic disorders. Over the years, Cerba Research has evolved to be the precision medicine partner to CROs, the biotechnology and pharmaceutical industry, and non-profit organizations with growing needs for complex clinical research programs.
Cerba Research CEO Mario Papillon said : “The acquisition of Viroclinics-DDL is a milestone for Cerba Research, as it enables us to build a comprehensive offering for our customers, with broader capabilities, best-in-class logistics, and key specific expertise that meet the healthcare industry needs. With our combined expertise in immuno-oncology and infectious / respiratory diseases, we are poised to accelerate therapy and vaccine development for biopharma customers while becoming the reference lab for cell and gene therapies of tomorrow. We are very much looking forward to onboarding the team of Viroclinics-DDL and together paving the way for new therapies.”
Viroclinics-DDL CEO Davide Molho added : “With Cerba Research, we have a new foundation for further global expansion to North America, Asia, and Africa with unrivalled expertise, capacity and capabilities. Together, we will be able to offer integrated solutions to the life science industry, accelerating antiviral, vaccine, and other R&D programs, while offering unmatched logistics solutions securing the integrity of fragile samples. Our 390+ scientists and experts look forward to joining Cerba Research in our continuous quest to provide the best possible science and service to our customers.”
The transaction is subject to regulatory approvals and customary conditions, such as completion of the consultation procedure with Central Works Council of Viroclinics-DDL. The acquisition is expected to close by end of Q1 2022.
###
About Cerba HealthCare
Cerba HealthCare, a leading global player in medical diagnosis, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier, and optimize the effectiveness of personalized medicine.
Every day, on 5 continents, the Group’s 12 000 employees sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health.
Cerba HealthCare, enlightening health
.
Additional information is available at www.cerbahealthcare.com
About Cerba Research
Cerba Research is a leading healthcare company with end-to-end drug development and diagnostic solutions to optimize R&D drug productivity and commercialization. Providing Early phase research, clinical development through central laboratory and diagnostic services, Assay and biomarker development and validation. Working with government agencies, non-government organizations as well as pharma and biotech organizations to change the shape of clinical development.
Cerba Research is part of Cerba HealthCare, a leading player in medical diagnosis.
For more information: www.cerbaresearch.com
About Viroclinics-DDL
Viroclinics-DDL is a leading specialty contract research organization, serving the biopharmaceutical community with a broad range of non-clinical research, clinical diagnostic, assay development, laboratory, and clinical trial logistic services. It offers its clients a global reach through a network of 38 processing laboratories. Viroclinics-DDL extensive experience in clinical and preclinical virology studies, including its specialty in respiratory and blood-borne viruses, puts the company at the forefront in supporting the development of vaccines, antibodies, antiviral compounds, and other therapies. Its in-house state-of-the-art preclinical and clinical BSL-2 and BSL-3 laboratories facilitate complex experiments with highly pathogenic organisms. Viroclinics-DDL is based in Rotterdam, Rijswijk and Schaijk in the Netherlands, and employs over 390 highly trained, dedicated scientists and technical experts.
For more information, visit www.viroclinics.com and www.ddl.nl .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216005574/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KAYTUS AI Compute Pod Wins 2026 iF Design Award and Red Dot Award, Setting a New Standard for AI Data Center28.4.2026 11:54:00 CEST | Press release
Delivering up to 130kW of liquid cooling per rack, the solution synchronizes cooling output with IT load in real time within seconds, to support high-density AI, large-scale computing, and HPC deployments, while reducing build time by 70% KAYTUS, a leading provider in AI infrastructure and liquid-cooling solutions, announced that its AI Compute Pod has received both the 2026 iF Design Award and Red Dot Award. This dual recognition not only stems from its outstanding performance in green, low-energy operation—achieving up to 130 kW cooling capacity per rack and a PUE as low as 1.1 through optimized thermal and power design—but also from its innovative approach to intelligent control and efficient O&M. The solution enables second-level synchronization between cooling and IT workloads, and leverages a dual-group control strategy to improve cooling energy efficiency by over 10%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260
Braskem to Showcase Sustainable Packaging Solutions at interpack 202628.4.2026 10:00:00 CEST | Press release
Braskem delivers scalable circular solutions that strengthen the packaging value chain and advance a lower‑carbon future. Braskem (B3: BRKM3, BRKM5, and BRKM6, NYSE: BAK, LATIBEX: XBRK) the largest polyolefins producer in the Americas, as well as a global market leader and pioneer producer of biopolymers on an industrial scale, will be at interpack 2026 in hall 9, booth A32, presenting packaging solutions made from bio-based, recycled and traditional polyolefins, enabling circular plastics, end-to-end. At interpack, Braskem will highlight I’m green™ bio‑based polyethylene grades specifically engineered for food‑contact applications, as well as Medcol V7040, a new grade for Healthcare and Hygiene. These innovations mark the first time Braskem has offered sustainably sourced sugarcane‑derived plastics for these segments. In an environment where packaging decisions are increasingly evaluated on both sustainability ambitions and business impact, Braskem positions itself as a materials part
Albion and Tecnotree Partner to Deliver Next-Generation VAS Platform for TELUS in North America28.4.2026 09:00:00 CEST | Press release
Albion, a leading provider of telecom managed services and solutions, today announced that TELUS has selected Albion, in partnership with Tecnotree, to deliver a next-generation Value-Added Services (VAS) platform, with an initial deployment of a voicemail application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428959214/en/ Albion and Tecnotree Partner to Deliver Next-Generation VAS Platform for TELUS in North America Under the engagement, Albion will deliver the solution leveraging Tecnotree’s proven VAS and digital services platform, supporting TELUS’ objectives to modernize service capabilities; enhance the customer experience; and ensure scalable, future-ready service delivery. As part of the deployment, Albion will provide end-to-end managed services, including platform operations, service assurance, and ongoing lifecycle management, ensuring high availability and performance for TELUS customers across North Ame
Budweiser Partners with Football Icons Erling Haaland and Jürgen Klopp to Unleash New “Let it Pour” Platform for FIFA World Cup 2026™28.4.2026 09:00:00 CEST | Press release
The platform extends across more than forty countries, bringing fans together with a new global film featuring Haaland and Klopp, limited edition apparel, and legendary fan experiences Today, Budweiser, the Official Beer Sponsor of the FIFA World Cup 2026™, unveiled its newest global football platform, “Let It Pour,” cracking open four years' worth of anticipation for the game’s biggest stage. Activating across more than forty countries, the global beer icon is supercharging celebrations with Bud FC fan events, The Bud Fan Store, and a new global film calling the world together to Let It Pour. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428722336/en/ Budweiser Partners with Football Icons Erling Haaland and Jürgen Klopp to Unleash New “Let it Pour” Platform for FIFA World Cup 2026™ “For over four decades, Budweiser has been part of the celebrations that define the FIFA World Cup™, be it on the pitch, in bars, or wherev
Roquette Showcases Its Expanded Consumer Healthcare Capabilities at Vitafoods Europe 202628.4.2026 09:00:00 CEST | Press release
Experts will share insights on consumer ready innovations for everyday health at booth 3F112 Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, will present its expanded portfolio at Vitafoods Europe 2026 which is taking place from May 5 to May 7 in Barcelona. Roquette’s offering is designed to help consumer healthcare brands stay future‑ready and accelerate consumer-centric innovations for everyday well-being. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428405433/en/ Credits to Roquette As consumer expectations rise and shelf competition intensifies, dietary supplement and over-the-counter (OTC) brands, as well as contract development and manufacturing organizations (CDMOs), face growing pressure to deliver clean-label products that combine efficacy, strong sensory experiences, regulatory confidence, and speed to market. At Vitafoods Europe 2026, Roquette will demonstrate it
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom